CDCA4抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: 293T and LOVO cell lysates, Primary antibody: P02487(CDCA4 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P02487(CDCA4 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

CDCA4 (Cell Division Cycle Associated 4), also known as SEI-3 or HSPC064. is a nuclear protein implicated in regulating cell cycle progression and transcriptional activity. It belongs to the CDCA protein family, which plays roles in cellular processes such as proliferation, differentiation, and apoptosis. CDCA4 interacts with key regulators like E2F transcription factors and the retinoblastoma (Rb) protein, influencing the G1/S phase transition and DNA replication. Studies suggest its involvement in modulating p53-dependent pathways, potentially linking it to tumor suppression or oncogenesis depending on cellular context.

CDCA4 antibodies are essential tools for investigating its expression, localization, and function in both physiological and pathological conditions. These antibodies are widely used in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to detect CDCA4 in cell lines, tissues, or clinical samples. Research has explored CDCA4's overexpression in certain cancers (e.g., hepatocellular carcinoma, glioblastoma), where it may promote proliferation or chemoresistance. Conversely, its downregulation has been associated with cellular senescence. The development of specific CDCA4 antibodies enables deeper insights into its dual roles in cancer biology and normal cell cycle regulation, supporting potential applications in biomarker discovery or therapeutic targeting.